BVAXFBiovaxys Technology Corp

$0.179
$0.00
(0.00%)
Today
Closed $0.179
$0.0215
(12.01%)
After Hours
Updated: 04:00 PM EDT
Mkt Cap$5.22M
Vol25,304.00
News
all
press releases
News Placeholder
Phase 1 Results Drive New Attention to Breast Cancer Play
Immuno oncology remains one of the most closely watched areas in biotechnology, particularly as researchers search for ways to enhance standard therapies rather than replace them outright. Even early stage clinical data can move markets when it points to improved outcomes in large, underserved patient populations.Shares of BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) are trading higher Wednesday after the company reported positive Phase 1 clinical results for its investigational immunotherapy maveropepimut S, or MVP S, in women with hormone receptor positive, HER2 negative stage II ...
AllPennyStocks
News Placeholder
Phase 1 Results Drive New Attention to Breast Cancer Play
Immuno oncology remains one of the most closely watched areas in biotechnology, particularly as researchers search for ways to enhance standard therapies rather than replace them outright. Even early stage clinical data can move markets when it points to improved outcomes in large, underserved patient populations.Shares of BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) are trading higher Wednesday after the company reported positive Phase 1 clinical results for its investigational immunotherapy maveropepimut S, or MVP S, in women with hormone receptor positive, HER2 negative stage II ...
AllPennyStocks
News Placeholder
Phase 1 Results Drive New Attention to Breast Cancer Play
Immuno oncology remains one of the most closely watched areas in biotechnology, particularly as researchers search for ways to enhance standard therapies rather than replace them outright. Even early stage clinical data can move markets when it points to improved outcomes in large, underserved patient populations.Shares of BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) are trading higher Wednesday after the company reported positive Phase 1 clinical results for its investigational immunotherapy maveropepimut S, or MVP S, in women with hormone receptor positive, HER2 negative stage II ...
AllPennyStocks
<
...
1
>

Advertisement|Remove ads.